FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
Data presented at the Science of Skin Summit indicate topical regimens and treatments yield visible improvements in laxity, crepiness, and perceived age among individuals taking GLP-1 therapies.